Dr. Walid I. El Ayass

Hematology Oncology | Hematology | Oncology
2003 Medical Pkwy, Suite 210, 
Annapolis, MD 
Accepting New Patients
Offers Telehealth
2003 Medical Pkwy, Suite 210, 
Annapolis, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Walid El Ayass is a Hematologist Oncology specialist and a Hematologist in Annapolis, Maryland. Dr. El Ayass is rated as an Experienced provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Adult Soft Tissue Sarcoma, and Bone Marrow Aspiration. Dr. El Ayass is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MD
Hospital Affiliations
Tidalhealth Peninsula Regional, Inc
Luminis Health Anne Arundel Medical Center, Inc
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

LUMINIS HEALTH MEDICAL GROUP, LLC
2003 Medical Pkwy, Suite 210, Annapolis, MD 21401
Other Locations
TIDALHEALTH SPECIALTY CARE LLC
100 E Carroll St, Salisbury, MD 21801

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 24, 2025
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 4 Less Clinical Trials

2 Total Publications

Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient-A case report.
Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient-A case report.
Journal: Clinical case reports
Published: May 27, 2021
Similar Doctors
Advanced in Prothrombin Deficiency
Dr. Joseph M. Haggerty
Hematology Oncology | Hematology | Oncology
Advanced in Prothrombin Deficiency
Dr. Joseph M. Haggerty
Hematology Oncology | Hematology | Oncology

Maryland Oncology Hematology PA

7350 Van Dusen Rd, Suite 370, 
Laurel, MD 
 (19.8 miles away)
301-982-9800
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joseph Haggerty is a Hematologist Oncology specialist and a Hematologist in Laurel, Maryland. Dr. Haggerty has been practicing medicine for over 44 years and is rated as a Distinguished provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Saddle Pulmonary Embolism, and Paget Disease of the Breast. Dr. Haggerty is currently accepting new patients.

Advanced in Prothrombin Deficiency
Dr. Deepnarayan Tiwarri
Hematology Oncology | Hematology | Oncology
Advanced in Prothrombin Deficiency
Dr. Deepnarayan Tiwarri
Hematology Oncology | Hematology | Oncology

Maryland Oncology Hematology PA

8926 Woodyard Rd, 
Clinton, MD 
 (24.7 miles away)
301-868-7911
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Deepnarayan Tiwarri is a Hematologist Oncology specialist and a Hematologist in Clinton, Maryland. Dr. Tiwarri is rated as a Distinguished provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Pulmonary Embolism, and Anemia. Dr. Tiwarri is currently accepting new patients.

Experienced in Prothrombin Deficiency
Dr. Vinni Juneja
Hematology Oncology | Hematology | Oncology
Experienced in Prothrombin Deficiency
Dr. Vinni Juneja
Hematology Oncology | Hematology | Oncology

Maryland Oncology Hematology PA

11886 Healing Way, 
Silver Spring, MD 
 (23.1 miles away)
301-933-3216
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Vinni Juneja is a Hematologist Oncology specialist and a Hematologist in Silver Spring, Maryland. Dr. Juneja is rated as a Distinguished provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Thrombocytopenia, and Paget Disease of the Breast. Dr. Juneja is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. El Ayass's expertise for a condition
ConditionClose
    View All 27 Advanced Conditions
    View All 119 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile